Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients.

J Pediatr Endocrinol Metab

Pediatrics Department and Endocrinology Service, Italian Hospital, Buenos Aires, Argentina.

Published: August 1999

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem.1999.12.4.555DOI Listing

Publication Analysis

Top Keywords

bisphosphonates children
4
children osteogenesis
4
osteogenesis imperfecta
4
imperfecta improve
4
improve bone
4
bone mineralization
4
mineralization bone
4
bone strength
4
strength report
4
report patients
4

Similar Publications

OI, or bone brittle disease, is characterized by increased mineralization of bone matrix independently of clinical severity. So, a beneficial effect of antiresorptive treatments such as bisphosphonates (BP) is questionable. We aim to compare the bone matrix characteristics before and after BP pamidronate (PAM).

View Article and Find Full Text PDF

[Metabolic bone diseases : what's new in 2024].

Rev Med Suisse

January 2025

Centre interdisciplinaire des maladies osseuses, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, 1011 Lausanne.

The epidemiology of femoral fractures is changing, with more femoral shaft fractures linked to high-risk physical exercise by an older population. Vitamin D given during pregnancy for the mother's health could benefit the child. Zoledronic acid is the most effective bisphosphonate.

View Article and Find Full Text PDF

Enhanced Osteoporosis Treatment via Nano Drug Coating Encapsulating GG.

ACS Appl Mater Interfaces

January 2025

Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College, Chongqing University Three Gorges Hospital, Chongqing Municipality Clinical Research Center for Geriatric Diseases, School of Medicine, Chongqing University, Chongqing 404000, China.

Osteoporosis is the most common systemic skeletal disorder, particularly associated with aging and postmenopausal women. With the growing knowledge about the gut-bone axis, the therapeutic strategies for osteoporosis have been shifted toward regulating gut microbiota to promote positive bone metabolism. Although GG (LGG) is widely reported to positively regulate bone metabolism by restoring the dysbiotic microbiome, oral administration is associated with sensitivity to gastric fluid and low bioavailability.

View Article and Find Full Text PDF

Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.

J Endocrinol Invest

January 2025

Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Aim: This review aims to overview factors contributing to TAO development and addresses the targeted diagnostic work-up and treatment management in adult thalassemic patients.

Results: Osteoporosis management in Thalassemia is challenging because several factors contributing to its pathogenesis should be considered and controlled starting from child- hood. A multidisciplinary approach is crucial.

View Article and Find Full Text PDF

Background Fragility fractures, often caused by osteoporosis, are a major public health concern among the growing population of the United Kingdom (UK). In addition to being a major source of illness and mortality, the rising incidence of osteoporosis places a heavy strain on healthcare systems if it is not adequately managed. In order to lower the risk of additional fractures, current guidelines place a strong emphasis on the timely evaluation and treatment of fragility fractures.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!